Mean baseline and post-treatment SF-36 PCS and MCS scores and SF-6D scores across trials
| RA | PsA | Psoriasis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Weeks 1–12 | Weeks 13–24 (ETN 25 mg)* | |||||||||
| ETN + MTX | MTX | ETN | Placebo | ETN 25 mg | ETN 50 mg | Placebo | ETN 25 mg | ETN 50 mg | Placebo | |
| PCS | ||||||||||
| Baseline | 29.3 | 29.5 | 33.6 | 33.4 | 49.5 | 48.8 | 49.0 | – | – | – |
| Endpoint | 43.0 | 40.2 | 43.4 | 34.7 | 52.8 | 52.7 | 49.6 | 52.9 | 52.5 | 52.0 |
| Mean change | 13.8† | 10.9† | 9.7† | 1.5 | 3.3† | 3.9† | 0.7 | 3.4† | 3.7† | 3.1† |
| p Value‡ | 0.003 | NS | 0.001 | NS | <0.0001 | <0.0001 | NS | |||
| MCS | ||||||||||
| Baseline | 42.1 | 42.2 | 51.5 | 49.3 | 48.4 | 47.2 | 46.1 | – | – | – |
| Endpoint | 48.9 | 48.3 | 54.1 | 50.3 | 51.0 | 50.6 | 46.5 | 51.1 | 51.4 | 49.1 |
| Mean change | 6.9† | 5.8† | 2.6† | 0.8 | 2.6† | 3.4† | 0.3 | 2.7† | 4.2† | 3.0† |
| p Value‡ | NS | NS | 0.040 | NS | <0.0001 | <0.0001 | NS | |||
| SF-6D | ||||||||||
| Baseline | 0.530 | 0.528 | 0.660 | 0.642 | 0.754 | 0.734 | 0.728 | – | – | – |
| Endpoint | 0.658 | 0.635 | 0.767 | 0.659 | 0.819 | 0.822 | 0.739 | 0.822 | 0.821 | 0.808 |
| Mean change | 0.128 | 0.121 | 0.105 | 0.018 | 0.065 | 0.084 | 0.011 | 0.066 | 0.083 | 0.077 |
| p Value‡ | <0.0001 | <0.0001 | <0.0001 | 0.079 | <0.0001 | <0.0001 | 0.285 | |||
↵* All patients received etanercept 25 mg twice a week during weeks 13–24, column headers represent original treatment assignment, p values are comparisons with week 12 values.
↵† Changes were greater than or equal to the minimal clinically important difference (MCID).
↵‡ p Value for change from baseline.
ETN, etanercept; MCS, mental component summary; MTX, methotrexate; NS, not significant; PCS, physical component summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-36, short form 36; SF-6D, health utility score based on mean scores across all eight domains of the SF-36.